GRIFOLS S A/S (NASDAQ:GRFS) was upgraded by stock analysts at Berenberg Bank from a “hold” rating to a “buy” rating in a research note issued on Thursday, Marketbeat Ratings reports.
A number of other equities research analysts have also issued reports on GRFS. BidaskClub lowered shares of GRIFOLS S A/S from a “hold” rating to a “sell” rating in a report on Thursday, June 28th. Zacks Investment Research upgraded shares of GRIFOLS S A/S from a “strong sell” rating to a “hold” rating in a research note on Wednesday, August 1st. JPMorgan Chase & Co. lowered shares of GRIFOLS S A/S from an “overweight” rating to a “neutral” rating in a research note on Wednesday, June 13th. Morgan Stanley dropped their price objective on shares of GRIFOLS S A/S from $22.00 to $20.00 and set an “underweight” rating on the stock in a research note on Monday, October 1st. Finally, UBS Group lowered shares of GRIFOLS S A/S from a “neutral” rating to a “sell” rating in a research note on Wednesday, October 3rd. Three investment analysts have rated the stock with a sell rating, three have issued a hold rating and four have given a buy rating to the company’s stock. The stock currently has an average rating of “Hold” and a consensus price target of $21.50.
Shares of GRFS stock traded down $0.09 during trading hours on Thursday, reaching $19.62. 1,584,548 shares of the stock traded hands, compared to its average volume of 872,042. GRIFOLS S A/S has a 1-year low of $18.69 and a 1-year high of $25.18. The company has a debt-to-equity ratio of 1.52, a current ratio of 2.90 and a quick ratio of 1.12. The firm has a market capitalization of $14.59 billion, a P/E ratio of 17.84, a P/E/G ratio of 1.49 and a beta of 1.21.
GRIFOLS S A/S (NASDAQ:GRFS) last released its quarterly earnings results on Friday, July 27th. The biotechnology company reported $0.34 earnings per share (EPS) for the quarter, meeting the Zacks’ consensus estimate of $0.34. GRIFOLS S A/S had a net margin of 16.55% and a return on equity of 18.32%. The business had revenue of $1.31 billion for the quarter, compared to analyst estimates of $1.35 billion. Sell-side analysts predict that GRIFOLS S A/S will post 1.21 EPS for the current fiscal year.
Institutional investors have recently added to or reduced their stakes in the business. Suntrust Banks Inc. acquired a new position in GRIFOLS S A/S in the 1st quarter valued at approximately $252,000. Financial Gravity Wealth Inc. bought a new stake in GRIFOLS S A/S in the first quarter worth approximately $282,000. Dynamic Technology Lab Private Ltd bought a new stake in GRIFOLS S A/S in the first quarter worth approximately $285,000. Verition Fund Management LLC bought a new stake in GRIFOLS S A/S in the first quarter worth approximately $324,000. Finally, Cubist Systematic Strategies LLC grew its position in GRIFOLS S A/S by 42.9% in the first quarter. Cubist Systematic Strategies LLC now owns 20,359 shares of the biotechnology company’s stock worth $432,000 after acquiring an additional 6,115 shares in the last quarter. Hedge funds and other institutional investors own 21.05% of the company’s stock.
GRIFOLS S A/S Company Profile
Grifols, SA, a specialty pharmaceutical company, develops, manufactures, and distributes biological medicines on plasma derived proteins in the United States, Canada, Spain, rest of the European Union, and internationally. The company operates through five segments: Bioscience, Diagnostic, Hospital, Bio Supplies, and Others.
See Also: Stop Order
Receive News & Ratings for GRIFOLS S A/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GRIFOLS S A/S and related companies with MarketBeat.com's FREE daily email newsletter.